Head to head
Kardigan vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: KARD · VRTX
KARD
Kardigan
11.54-7.83%
1-year price shape — not enough history yet
Quant Rating C · 0/100
vs
VRTX
Vertex Pharmaceuticals
515.02-1.08%
1-year price shape — +22% over the period
Quant Rating C · 68/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals earns the most per share.
| KARD | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Biotechnology |
| Last price | 11.54 | 515.02 |
| Change today | -7.83% | -1.08% |
| 1-year return | -- | +22.0% |
| Market cap | $1.08B | $130.58B |
| 52-week range | 11.49 – 27.00 | 412.27 – 568.67 |
| Valuation | ||
| P/E (TTM) | -3.76 | 33.14 |
| P/E percentile, own 5-yr range | 83rd | 99th |
| P/B | 1.89 | 6.25 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -2.19 | 15.32 |
| Net profit (TTM) | $-204.88M | $3.88B |
| Revenue (TTM) | -- | $12.95B |
| Provider revenue period date | 2026-06-29 | 2026-09-29 |
| Revenue growth (YoY) | -- | +11.8% |
| Gross margin | -- | 85.5% |
| Operating margin | -- | 33.1% |
| Net margin | -- | 30.7% |
| Free cash flow (TTM) | -- | $3.20B |
| Provider cash-flow period date | 2026-06-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 83.5% | 96.8% |
| Insider activity (12mo) | 16 buy / 0 sell | 28 buy / 22 sell |
| Short interest (% of float) | 6.1% | 1.9% |
| Analyst consensus | 100% buy (8) | 95% buy / 5% hold (21) |
| Analyst price target | $41 (+253%) | $624 (+21%) |
| StockVane view | ||
| StockVane Quant Rating | C (0) | C (68) |
| Company | ||
| Employees | 380 | 6,400 |
| Founded | 2023 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.